Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Limited has requested a trading halt for its securities as it prepares for an entitlement offer, with the expectation that normal trading will resume on April 16, 2024. The temporary halt is to facilitate the company’s capital raising initiative, details of which will be announced to the market to lift the halt. Amplia specializes in developing FAK inhibitors for the treatment of cancer and fibrosis, focusing on diseases such as pancreatic and ovarian cancer.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
